Previous 10 | Next 10 |
Shares of Tricida, Inc. (NASDAQ: TCDA) are tumbling 38.5% at 1:45 p.m. EDT on Thursday after the pharmaceutical company disclosed the Food and Drug Administration (FDA) has found deficiencies in its application for approval of veverimer. Designed to bind to and remove excess acid in chronic...
Gainers: InnerWorkings (NASDAQ: INWK ) +117% . More news on: InnerWorkings, Inc., Heat Biologics, Inc., Boxlight Corporation, Stocks on the move, , Read more ...
Tricida (NASDAQ: TCDA ) -33% after FDA flags deficiencies in Veverimer. More news on: Tricida, Inc., INmune Bio, Inc., WISeKey International Holding AG, Stocks on the move, , Read more ...
Tricida (NASDAQ: TCDA ) shares tank ~33% AH in reaction to the FDA notification regarding “deficiencies” regarding labeling and postmarketing requirements for veverimer for metabolic acidosis in chronic kidney disease patients. Though the not...
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today th...
Tricida, Inc. (Nasdaq: TCDA) announced that, due to public health concerns relating to the coronavirus pandemic (COVID-19) and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders (the “Annual Meeting”) will be held in a vir...
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:40 pm PT / 4:40 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives....
Tricida, Inc. (Nasdaq: TCDA) , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced t...
Tricida (NASDAQ: TCDA ) has priced its $175M aggregate principal amount of its 3.50% Convertible Senior Notes due 2027. More news on: Tricida, Inc., Healthcare stocks news, , Read more ...
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced th...
News, Short Squeeze, Breakout and More Instantly...
Penny Stocks Under $1 It’s another choppy session in the stock market today, but penny stocks remain a shining light for day traders. Despite the S&P, Nasdaq, and Dow taking a hiatus from a two-day recession-fueled sell-off, traders are getting back in the saddle in preparation for...